公司資料
Adicet Bio 股價、新聞與催化劑
- 股票代碼:
- ACET
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
6.64 USD (-7.00%)
收盤價
最後更新: 2026年10月1日
75.8M USD
市值
股價為何變動
截至 2026年10月1日，ACET 下跌 7.00%，收於 $6.64。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Allogeneic Gamma Delta T-Cell Company
Adicet Bio develops off-the-shelf gamma delta T-cell therapies engineered with chimeric antigen receptors. The platform is intended to combine readily available allogeneic manufacturing with innate and adaptive immune activity in autoimmune disease and cancer.
Prula-Cel Autoimmune Program
Prula-cel is an allogeneic CD20-targeted gamma delta CAR-T therapy being evaluated in systemic lupus erythematosus, lupus nephritis, and other autoimmune conditions. The program seeks to achieve deep B-cell depletion and durable immune reset without individualized autologous manufacturing.
Outpatient Treatment Potential
FDA alignment allows current and future lupus nephritis and systemic lupus erythematosus patients to receive prula-cel in an outpatient setting. If supported by clinical data, this operating model could reduce treatment complexity relative to cell therapies requiring prolonged inpatient care.
ADI-212 Solid-Tumor Program
ADI-212 is a gene-edited, armored allogeneic gamma delta CAR-T candidate targeting PSMA in metastatic castration-resistant prostate cancer. The design combines a tumor-specific binder, membrane-tethered IL-12, and MED12 disruption to improve activity within the solid-tumor microenvironment.
In Vivo CAR-T Research
Adicet is also developing an in vivo CAR-T platform for hematologic malignancies and solid tumors. This research aims to generate therapeutic immune cells directly inside the patient and potentially eliminate ex vivo manufacturing and conditioning steps.
未來催化劑
- Phase 1 prula-cel clinical update in lupus nephritis and systemic lupus erythematosus in the third quarter of 2026.
- Initiation of a potential pivotal prula-cel program in lupus nephritis in the second half of 2026, subject to regulatory clearance.
- Regulatory submission for ADI-212 in metastatic castration-resistant prostate cancer in the third quarter of 2026.
- Initiation of the Phase 1 ADI-212 study in the fourth quarter of 2026, subject to regulatory clearance.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。